Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

Cancer Cell(2021)10.1016/j.ccell.2021.12.005Source: DataRank Database

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity is a research paper published in Cancer Cell (2021). On theSindex it has a DataRank of 0. It has been cited 164 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access164 citations

Download PDF

Cite:

Linked data & code

geo gen cellosaurus pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (26 grants)OA: hybridTopics (30)IDs (PubMed, PMC)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (41)

Kristopher R. Bosse ORCID,Zhongyu Zhu ORCID,Doncho V. Zhelev ORCID,Robbie G. Majzner ORCID,Molly Radosevich ORCID

Live enrichment

PubMed:34971569 PMC:PMC9092726

National Cancer Institute

Grant: K08CA230223

NIH

Grant: K08CA230188

NIH

Grant: CA220500

NIH

Grant: P01CA217959-01

NIH

Grant: U54 CA232568-01

Canada Research Chairs

Grant: P-91650709

Damon Runyon Cancer Research Foundation

Grant: PST-07-16

NCI NIH HHS

Grant: P01 CA217959

Austrian Science Fund FWF

Grant: P 35072

NCI NIH HHS

Grant: R35 CA220500

NCI NIH HHS

Grant: U54 CA232568

National Institutes of Health

Grant: 5K08CA230188-03

Single cell epigenomics in cancer immunity and immunotherapy

National Institutes of Health

Grant: 7P01CA217959-04

Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance

National Institutes of Health

Grant: 5K08CA230223-02

Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma

National Institutes of Health

Grant: 3U54CA232568-01S4

Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers

Cancer Research Institute

Christian Doppler Forschungsgesellschaft

German Cancer Aid

Alex's Lemonade Stand Foundation for Childhood Cancer

Howard Hughes Medical Institute

Austrian National Foundation for Research Technology and Development

Burroughs Wellcome Fund

Virginia and D K Ludwig Fund for Cancer Research

CIFAR

Entertainment Industry Foundation

Stanford University

hybridLicense: cc-by-nc-nd

publisherhttp://www.cell.com/article/S1535610821006589/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535610821006589?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610821006589?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9092726

https://doi.org/10.1016/j.ccell.2021.12.005

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

T-LymphocytesCell Line, TumorAnimalsHumansNeuroblastomaReceptors, Antigen, T-CellImmunotherapyImmunotherapy, AdoptiveXenograft Model Antitumor AssaysGlypicansReceptors, Chimeric Antigen

Keywords

ImmunotherapyNeuroblastomaOncofetal AntigenChimeric Antigen ReceptorAntigen DensityCar T cellGpc2Glypican-2Receptors, Chimeric AntigenT-LymphocytesReceptors, Antigen, T-CellImmunotherapy, AdoptiveXenograft Model Antitumor AssaysGlypicansCell Line, TumorAnimalsHumans

Sustainable Development Goals

SDG 3: 3. Good health